For decades, federal law required an in-person medical evaluation before a doctor could prescribe controlled substances like Adderall, Xanax, or opioid pain medication. The pandemic forced the DEA to temporarily waive that rule, opening the door to telehealth prescribing of controlled substances on a scale never seen before. More than 40 million Americans received a controlled substance prescription through telehealth during the pandemic era, according to the Drug Enforcement Administration. Now the DEA telemedicine rule news that matters most is what happens as those temporary flexibilities are formalized into permanent policy. The outcome will determine whether millions of patients can continue accessing ADHD medications, anxiety treatments, and addiction therapy through their screens or must return to in-person visits. For an overview of how telehealth works across conditions and platforms, our telehealth guide provides the foundation.
The Ryan Haight Act: Why These Rules Exist
The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 was passed after an 18-year-old in California died from an overdose of drugs purchased from an online pharmacy that prescribed opioids without ever seeing him in person. The law established a clear rule: a practitioner must conduct at least one in-person medical evaluation before prescribing a controlled substance via the internet.
The law included a narrow telemedicine exception, but it required a special DEA registration process that was never fully implemented. For more than a decade, the exception existed on paper but was essentially unusable in practice. This meant controlled substances could not be legally prescribed via telehealth under normal circumstances, creating a significant barrier for patients in rural areas, those with mobility limitations, and anyone who struggled to access in-person psychiatric or pain management care.
When COVID-19 arrived in March 2020, the DEA activated its public health emergency authority to temporarily suspend the in-person requirement for all controlled substance schedules. This single regulatory action unlocked telehealth prescribing for the most commonly needed controlled medications and transformed how millions of Americans received treatment for ADHD, anxiety, chronic pain, and opioid use disorder.
What the DEA Changed During the Pandemic
From March 2020 through the end of the declared public health emergency in May 2023, the DEA allowed any DEA-registered practitioner to prescribe controlled substances via telehealth without an in-person exam. No special registration was needed. The only requirement was that the prescriber held a valid DEA registration and a state medical license where the patient was located.
The impact was enormous. Telehealth prescribing of Schedule II stimulants (like Adderall, Vyvanse, and Ritalin for ADHD) increased by over 500% during this period, according to CDC surveillance data. ADHD diagnoses in adults surged as telehealth removed the access barriers that had previously prevented many adults from seeking evaluation. Platforms like Done, Cerebral, and Ahead built entire business models around telehealth ADHD diagnosis and treatment.
Buprenorphine prescribing for opioid addiction treatment via telehealth also surged, with research published in JAMA Network Open showing that telehealth buprenorphine patients had comparable or better retention in treatment compared to in-person patients. This finding was significant because opioid use disorder treatment is time-sensitive — patients who face barriers to access are at higher risk of relapse and overdose death.
The pandemic period also revealed a darker side. Some telehealth platforms were accused of prescribing stimulants and other controlled substances with minimal clinical evaluation, fueling concerns about diversion and misuse. Cerebral and Done both faced scrutiny from the DEA, and reports of stimulant shortages raised questions about whether telehealth was driving over-prescribing. These concerns directly shaped the regulatory framework that followed.
The Current DEA Telemedicine Framework
After multiple rounds of proposed rules, public comment periods (which generated over 38,000 comments), and deadline extensions, the DEA has established a framework that attempts to balance patient access with abuse prevention. Here’s where things stand as of 2026:
Non-Stimulant Controlled Substances (Schedules III-V)
For Schedule III-V controlled substances, the DEA allows telehealth prescribing with certain guardrails. This category includes buprenorphine for opioid use disorder, testosterone (when clinically indicated), certain sleep medications, benzodiazepines in lower schedules, and medications like gabapentin (where scheduled by state). Providers must be DEA-registered, maintain proper medical records, follow state-specific telehealth prescribing regulations, and establish a legitimate provider-patient relationship through a thorough evaluation.
Schedule II Stimulants (ADHD Medications)
This is where the rules are strictest and most controversial. The DEA has implemented a tiered approach for Schedule II stimulants including Adderall, Vyvanse, Ritalin, and Concerta:
- Providers can prescribe an initial limited supply (typically a 30-day prescription) of Schedule II stimulants via telehealth after conducting a thorough clinical evaluation
- Patients must complete an in-person evaluation within a specified window (generally 180 days of the initial telehealth prescription) to continue receiving refills
- The in-person visit can be with the telehealth prescriber, another DEA-registered provider, or a referring physician, provided appropriate records are shared
- After the qualifying in-person visit, ongoing prescriptions can be managed via telehealth with periodic in-person check-ins as clinically appropriate
The specifics of these requirements have been subject to ongoing discussion, and the DEA has extended interim timelines multiple times as it works toward final rules. State regulations add another layer of complexity, as some states have imposed their own requirements that may be stricter than the federal framework.
Opioids
Opioid prescribing via telehealth remains the most restricted category. While buprenorphine for addiction treatment has received favorable treatment from regulators (given the life-saving nature of medication-assisted treatment for opioid use disorder), new opioid prescriptions for pain management generally still require in-person evaluation. The DEA has been firm that telehealth opioid prescribing for pain carries the highest risk of diversion and misuse, and the agency has shown little appetite for loosening these restrictions.
What This Means for Patients
If you currently receive a controlled substance prescription through telehealth, here’s what you need to know based on your specific situation:
ADHD patients: You may be able to initiate or continue stimulant treatment via telehealth, but expect to need an in-person visit within the first six months of treatment. Platforms like Done, Cerebral, and ADHD Online have adjusted their models to comply with the in-person requirement, often partnering with local clinics, urgent care centers, or primary care practices for the qualifying visit. Some platforms help coordinate this in-person visit as part of their service; others leave it to the patient. Ask your platform specifically how they handle the in-person requirement.
Patients on buprenorphine/Suboxone: Access has generally been preserved. Congress and the DEA have treated buprenorphine differently because restricting access could directly lead to overdose deaths. The bipartisan Mainstreaming Addiction Treatment (MAT) Act, passed in 2023, eliminated the separate DEA waiver requirement for prescribing buprenorphine, and telehealth prescribing of buprenorphine remains available. Many addiction treatment telehealth providers can continue prescribing without an in-person requirement, though this varies by state.
Anxiety and sleep medication patients: Benzodiazepines (like Xanax, Klonopin, Ativan) and certain sleep medications (like zolpidem) fall under different schedules and their telehealth prescribing rules vary. Many telehealth providers have shifted away from benzodiazepines in favor of non-controlled alternatives (SSRIs, SNRIs, buspirone, hydroxyzine) that can be prescribed without the same regulatory restrictions. If you currently receive a benzodiazepine through telehealth, discuss your provider’s compliance with current rules.
For more on how these changes affect telehealth costs and insurance coverage, our healthcare costs guide covers cost considerations across different care models.
How Telehealth Platforms Have Adapted
The evolving DEA rules have forced telehealth companies to fundamentally restructure their business models. Several platforms that built their businesses on telehealth-only controlled substance prescribing have pivoted significantly:
ADHD-focused platforms: Cerebral, Done, and Ahead now partner with in-person clinics or require patients to complete a qualifying visit with a local provider. Some have added hybrid models where the initial evaluation can be conducted in person with subsequent follow-ups virtual. Cerebral, after facing regulatory scrutiny in 2022-2023, implemented more conservative prescribing protocols and hired additional compliance staff.
Opioid use disorder treatment platforms: Bicycle Health, Workit Health, and Eleanor Health have largely maintained telehealth access for buprenorphine prescribing, given the more favorable regulatory treatment of addiction medications. These platforms have been vocal advocates for maintaining telehealth access for substance use treatment.
Major insurer-backed platforms: MDLIVE, Teladoc, and Optum Virtual Care have always been more conservative about controlled substance prescribing and have largely operated within the new framework from the start. These platforms typically refer patients to in-network psychiatrists for controlled substance management rather than prescribing through their on-demand urgent care services.
The market has also seen new entrants that specialize in the hybrid telehealth-plus-in-person model, offering initial in-person evaluations with ongoing telehealth management. This approach may represent the long-term equilibrium for controlled substance prescribing via telehealth.
State-Level Variation
DEA rules set the federal floor, but states can impose stricter requirements. Some states require an in-person visit before any controlled substance can be prescribed via telehealth, regardless of the DEA’s position. Others have adopted more permissive approaches that align with or exceed federal flexibility.
States like Alabama, Louisiana, and Texas have historically maintained stricter telehealth prescribing rules, while states like Arizona, Florida, and Colorado have been more permissive. The patchwork of state regulations creates complexity for patients who travel or relocate, and for telehealth platforms that operate nationally.
Before relying on telehealth for controlled substance prescriptions, check your state medical board’s telemedicine prescribing rules. Your telehealth platform should also flag any state-specific requirements during the intake process. The Federation of State Medical Boards (FSMB) maintains a regularly updated resource on state telehealth policies that patients and providers can reference.
The Broader Policy Debate
The DEA’s telemedicine rulemaking has sparked a broader debate about how to balance access, safety, and innovation in healthcare. Patient advocacy organizations, mental health groups, and telehealth companies argue that in-person requirements create unnecessary barriers to care, particularly for patients in rural areas, those with disabilities, and people with conditions (like severe anxiety or agoraphobia) that make in-person visits especially difficult.
On the other side, the DEA, some medical societies, and addiction medicine experts point to evidence of over-prescribing during the pandemic era, stimulant shortages that affected patients with legitimate prescriptions, and the potential for telehealth-based “pill mills” that prioritize volume over clinical appropriateness.
The compromise that appears to be emerging — initial telehealth access with eventual in-person verification — satisfies neither camp entirely but may represent a workable middle ground. Congressional interest in permanent telehealth rules for controlled substances remains high, with multiple bills introduced that would codify various approaches.
Frequently Asked Questions
Can a telehealth doctor prescribe Adderall?
Under current DEA rules, a telehealth provider can prescribe a limited initial supply of Adderall (typically 30 days) after a thorough clinical evaluation. To continue the prescription, you’ll generally need to complete an in-person evaluation within a specified timeframe (often 180 days). Rules vary by state and are subject to change as the DEA finalizes its permanent framework.
Can I get Xanax through telehealth?
Some telehealth providers can prescribe benzodiazepines like Xanax, but many are cautious due to abuse potential, regulatory scrutiny, and clinical guidelines that recommend non-benzodiazepine alternatives as first-line treatment for anxiety. Your provider may recommend SSRIs, SNRIs, buspirone, or hydroxyzine before considering a benzodiazepine. If a benzodiazepine is clinically appropriate, the prescribing rules depend on the drug’s schedule and your state’s regulations.
Do the DEA telemedicine rules affect Suboxone prescribing?
Buprenorphine-based medications like Suboxone have received more favorable treatment in the DEA’s telemedicine framework. The MAT Act eliminated the separate waiver requirement for prescribing buprenorphine, and many patients can continue receiving buprenorphine prescriptions through telehealth without an in-person visit. Requirements vary by state and specific clinical circumstances.
Are the DEA telemedicine rules permanent?
The DEA has been working toward permanent telemedicine prescribing rules since the end of the public health emergency in 2023. Final rules have been issued for some medication categories, while others remain subject to interim policies, extensions, and ongoing rulemaking. The situation continues to evolve as of 2026, and patients should stay in contact with their prescribing provider about any changes that may affect their treatment.
What happens if my telehealth provider can’t prescribe my medication anymore?
If regulatory changes affect your telehealth provider’s ability to prescribe your medication, they should help you transition to a compliant arrangement. This might mean completing an in-person visit to continue telehealth prescribing, transferring your care to a local in-person provider, or switching to a non-controlled alternative medication. Never stop a controlled medication abruptly without medical guidance.
What to Do Next
If you receive controlled substance prescriptions through telehealth, confirm with your provider that they’re compliant with current DEA rules and ask specifically what steps you may need to take to maintain your prescription. Find out whether you’ll need an in-person visit and what the timeline is. If you’re starting a new controlled substance via telehealth, understand upfront that a follow-up in-person evaluation may be required and plan accordingly. Staying informed about these rules protects your access to medication and ensures your treatment isn’t interrupted by a regulatory surprise. Your telehealth provider should be transparent about these requirements; if they’re evasive about compliance, consider that a red flag.